WO1999066040A1 - Immunomodulator polypeptide, zsig57 - Google Patents
Immunomodulator polypeptide, zsig57 Download PDFInfo
- Publication number
- WO1999066040A1 WO1999066040A1 PCT/US1999/011337 US9911337W WO9966040A1 WO 1999066040 A1 WO1999066040 A1 WO 1999066040A1 US 9911337 W US9911337 W US 9911337W WO 9966040 A1 WO9966040 A1 WO 9966040A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- seq
- zsig57
- polypeptide
- sequence
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 377
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 351
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 337
- 229940121354 immunomodulator Drugs 0.000 title description 5
- 239000002955 immunomodulating agent Substances 0.000 title description 4
- 230000002584 immunomodulator Effects 0.000 title description 4
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 167
- 238000000034 method Methods 0.000 claims abstract description 124
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 107
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 72
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 72
- 239000002157 polynucleotide Substances 0.000 claims abstract description 72
- 210000004027 cell Anatomy 0.000 claims description 260
- 150000001413 amino acids Chemical class 0.000 claims description 132
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 102
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 69
- 239000013598 vector Substances 0.000 claims description 50
- 239000002773 nucleotide Substances 0.000 claims description 41
- 125000003729 nucleotide group Chemical group 0.000 claims description 41
- 239000002299 complementary DNA Substances 0.000 claims description 38
- 239000013612 plasmid Substances 0.000 claims description 36
- 125000000539 amino acid group Chemical group 0.000 claims description 31
- 230000003248 secreting effect Effects 0.000 claims description 30
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 24
- 108020001507 fusion proteins Proteins 0.000 claims description 24
- 102000037865 fusion proteins Human genes 0.000 claims description 24
- 238000006467 substitution reaction Methods 0.000 claims description 24
- 239000013604 expression vector Substances 0.000 claims description 20
- 241001465754 Metazoa Species 0.000 claims description 19
- 238000013518 transcription Methods 0.000 claims description 13
- 230000035897 transcription Effects 0.000 claims description 13
- 238000012258 culturing Methods 0.000 claims description 12
- 239000011159 matrix material Substances 0.000 claims description 12
- 230000028993 immune response Effects 0.000 claims description 7
- 210000004748 cultured cell Anatomy 0.000 claims description 4
- 230000002103 transcriptional effect Effects 0.000 claims description 4
- 239000013043 chemical agent Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 10
- 102000018358 immunoglobulin Human genes 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 9
- 210000000349 chromosome Anatomy 0.000 abstract description 7
- 108020004414 DNA Proteins 0.000 description 119
- 235000018102 proteins Nutrition 0.000 description 102
- 235000001014 amino acid Nutrition 0.000 description 99
- 229940024606 amino acid Drugs 0.000 description 86
- 210000001519 tissue Anatomy 0.000 description 50
- 241000700605 Viruses Species 0.000 description 44
- 230000027455 binding Effects 0.000 description 44
- 108020004635 Complementary DNA Proteins 0.000 description 40
- 102000005962 receptors Human genes 0.000 description 40
- 108020003175 receptors Proteins 0.000 description 40
- 239000005557 antagonist Substances 0.000 description 39
- 239000012634 fragment Substances 0.000 description 39
- 230000014509 gene expression Effects 0.000 description 38
- 238000010804 cDNA synthesis Methods 0.000 description 37
- 230000000694 effects Effects 0.000 description 37
- 238000003556 assay Methods 0.000 description 36
- 239000000556 agonist Substances 0.000 description 33
- 239000000243 solution Substances 0.000 description 31
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 27
- 230000000295 complement effect Effects 0.000 description 26
- 238000001727 in vivo Methods 0.000 description 26
- 239000000203 mixture Substances 0.000 description 26
- 239000000499 gel Substances 0.000 description 25
- 239000000523 sample Substances 0.000 description 25
- 239000003446 ligand Substances 0.000 description 24
- 241000701161 unidentified adenovirus Species 0.000 description 24
- 210000001185 bone marrow Anatomy 0.000 description 22
- 108020004705 Codon Proteins 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- 230000004927 fusion Effects 0.000 description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 description 19
- 210000000265 leukocyte Anatomy 0.000 description 18
- 241000701447 unidentified baculovirus Species 0.000 description 18
- 241001452677 Ogataea methanolica Species 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 17
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 16
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 16
- 102400001107 Secretory component Human genes 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 16
- 239000013615 primer Substances 0.000 description 16
- 238000000746 purification Methods 0.000 description 16
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 15
- 241000894007 species Species 0.000 description 15
- 230000004913 activation Effects 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- 238000012546 transfer Methods 0.000 description 14
- 238000001262 western blot Methods 0.000 description 14
- 230000008859 change Effects 0.000 description 13
- 239000006166 lysate Substances 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 238000001890 transfection Methods 0.000 description 13
- 229920000936 Agarose Polymers 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 210000000813 small intestine Anatomy 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 108091060211 Expressed sequence tag Proteins 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 11
- 239000003550 marker Substances 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000007017 scission Effects 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 10
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 10
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 10
- 230000037361 pathway Effects 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 239000011347 resin Substances 0.000 description 10
- 229920005989 resin Polymers 0.000 description 10
- 230000019491 signal transduction Effects 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- 108010001789 Calcitonin Receptors Proteins 0.000 description 9
- 102100038520 Calcitonin receptor Human genes 0.000 description 9
- 230000002391 anti-complement effect Effects 0.000 description 9
- 108010008730 anticomplement Proteins 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 230000036755 cellular response Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 239000008188 pellet Substances 0.000 description 9
- 230000009466 transformation Effects 0.000 description 9
- 230000014616 translation Effects 0.000 description 9
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 101000990034 Homo sapiens CMRF35-like molecule 6 Proteins 0.000 description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 108091027981 Response element Proteins 0.000 description 8
- 229940072056 alginate Drugs 0.000 description 8
- 235000010443 alginic acid Nutrition 0.000 description 8
- 229920000615 alginic acid Polymers 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 8
- 231100000433 cytotoxic Toxicity 0.000 description 8
- 230000001472 cytotoxic effect Effects 0.000 description 8
- 230000002950 deficient Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000004520 electroporation Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 8
- 239000005556 hormone Substances 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 210000004962 mammalian cell Anatomy 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 230000005855 radiation Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- 238000012384 transportation and delivery Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229910001868 water Inorganic materials 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 241000238631 Hexapoda Species 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 229920002684 Sepharose Polymers 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 230000000120 cytopathologic effect Effects 0.000 description 7
- 239000003599 detergent Substances 0.000 description 7
- 210000003527 eukaryotic cell Anatomy 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000011830 transgenic mouse model Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 6
- 230000030741 antigen processing and presentation Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000006539 extracellular acidification Effects 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 101100437118 Arabidopsis thaliana AUG1 gene Proteins 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 5
- 108091029865 Exogenous DNA Proteins 0.000 description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- 241000256251 Spodoptera frugiperda Species 0.000 description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000003171 anti-complementary effect Effects 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 239000004599 antimicrobial Substances 0.000 description 5
- 108091008324 binding proteins Proteins 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 102000058029 human CD300C Human genes 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 229920002521 macromolecule Polymers 0.000 description 5
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 230000001131 transforming effect Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 101710094503 Metallothionein-1 Proteins 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 108010007389 Trefoil Factors Proteins 0.000 description 4
- 102000007641 Trefoil Factors Human genes 0.000 description 4
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 229940095074 cyclic amp Drugs 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 235000020776 essential amino acid Nutrition 0.000 description 4
- 239000003797 essential amino acid Substances 0.000 description 4
- 210000002907 exocrine cell Anatomy 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 229960003136 leucine Drugs 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 210000004412 neuroendocrine cell Anatomy 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000011164 ossification Effects 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 210000005253 yeast cell Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102100029382 CMRF35-like molecule 6 Human genes 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 102100035882 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 3
- 241000702421 Dependoparvovirus Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102100035187 Polymeric immunoglobulin receptor Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108700005078 Synthetic Genes Proteins 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 108700005077 Viral Genes Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000001261 affinity purification Methods 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 210000004413 cardiac myocyte Anatomy 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229960002086 dextran Drugs 0.000 description 3
- -1 digested Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 3
- 108010052968 leupeptin Proteins 0.000 description 3
- 108020001756 ligand binding domains Proteins 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 230000000955 neuroendocrine Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 210000001322 periplasm Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 230000031998 transcytosis Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- PDRJLZDUOULRHE-ZETCQYMHSA-N (2s)-2-amino-3-pyridin-2-ylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=N1 PDRJLZDUOULRHE-ZETCQYMHSA-N 0.000 description 2
- DFZVZEMNPGABKO-ZETCQYMHSA-N (2s)-2-amino-3-pyridin-3-ylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CN=C1 DFZVZEMNPGABKO-ZETCQYMHSA-N 0.000 description 2
- FQFVANSXYKWQOT-ZETCQYMHSA-N (2s)-2-azaniumyl-3-pyridin-4-ylpropanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=NC=C1 FQFVANSXYKWQOT-ZETCQYMHSA-N 0.000 description 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 2
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 101100437119 Arabidopsis thaliana AUG2 gene Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 235000004035 Cryptotaenia japonica Nutrition 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 108010067193 Formaldehyde transketolase Proteins 0.000 description 2
- 108090000698 Formate Dehydrogenases Proteins 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 108091092878 Microsatellite Proteins 0.000 description 2
- 102000015728 Mucins Human genes 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000016222 Pancreatic disease Diseases 0.000 description 2
- 102100027330 Phosphoribosylaminoimidazole carboxylase Human genes 0.000 description 2
- 101710182846 Polyhedrin Proteins 0.000 description 2
- 108010046644 Polymeric Immunoglobulin Receptors Proteins 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108700025832 Serum Response Element Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 235000015724 Trifolium pratense Nutrition 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 230000004640 cellular pathway Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000012501 chromatography medium Substances 0.000 description 2
- PMMYEEVYMWASQN-IMJSIDKUSA-N cis-4-Hydroxy-L-proline Chemical compound O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000000447 dimerizing effect Effects 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 108010044853 histidine-rich proteins Proteins 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229940051875 mucins Drugs 0.000 description 2
- 230000004678 mucosal integrity Effects 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000009707 neogenesis Effects 0.000 description 2
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000037434 nonsense mutation Effects 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 150000002924 oxiranes Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229950000964 pepstatin Drugs 0.000 description 2
- 108010091212 pepstatin Proteins 0.000 description 2
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 108010035774 phosphoribosylaminoimidazole carboxylase Proteins 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 238000013391 scatchard analysis Methods 0.000 description 2
- 238000002821 scintillation proximity assay Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000012134 supernatant fraction Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000037905 systemic hypertension Diseases 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- UJXJZOCXEZPHIE-YFKPBYRVSA-N (2s)-2-(2-hydroxyethylamino)-4-sulfanylbutanoic acid Chemical compound OCCN[C@H](C(O)=O)CCS UJXJZOCXEZPHIE-YFKPBYRVSA-N 0.000 description 1
- KUHSEZKIEJYEHN-BXRBKJIMSA-N (2s)-2-amino-3-hydroxypropanoic acid;(2s)-2-aminopropanoic acid Chemical compound C[C@H](N)C(O)=O.OC[C@H](N)C(O)=O KUHSEZKIEJYEHN-BXRBKJIMSA-N 0.000 description 1
- JQFLYFRHDIHZFZ-RXMQYKEDSA-N (2s)-3,3-dimethylpyrrolidine-2-carboxylic acid Chemical compound CC1(C)CCN[C@@H]1C(O)=O JQFLYFRHDIHZFZ-RXMQYKEDSA-N 0.000 description 1
- CNPSFBUUYIVHAP-AKGZTFGVSA-N (2s)-3-methylpyrrolidine-2-carboxylic acid Chemical compound CC1CCN[C@@H]1C(O)=O CNPSFBUUYIVHAP-AKGZTFGVSA-N 0.000 description 1
- FXGZFWDCXQRZKI-VKHMYHEASA-N (2s)-5-amino-2-nitramido-5-oxopentanoic acid Chemical compound NC(=O)CC[C@@H](C(O)=O)N[N+]([O-])=O FXGZFWDCXQRZKI-VKHMYHEASA-N 0.000 description 1
- CCAIIPMIAFGKSI-DMTCNVIQSA-N (2s,3r)-3-hydroxy-2-(methylazaniumyl)butanoate Chemical compound CN[C@@H]([C@@H](C)O)C(O)=O CCAIIPMIAFGKSI-DMTCNVIQSA-N 0.000 description 1
- CNPSFBUUYIVHAP-WHFBIAKZSA-N (2s,3s)-3-methylpyrrolidin-1-ium-2-carboxylate Chemical compound C[C@H]1CCN[C@@H]1C(O)=O CNPSFBUUYIVHAP-WHFBIAKZSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 1
- OMGHIGVFLOPEHJ-UHFFFAOYSA-N 2,5-dihydro-1h-pyrrol-1-ium-2-carboxylate Chemical compound OC(=O)C1NCC=C1 OMGHIGVFLOPEHJ-UHFFFAOYSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- XEVFXAFXZZYFSX-UHFFFAOYSA-N 3-azabicyclo[2.1.1]hexane-4-carboxylic acid Chemical compound C1C2CC1(C(=O)O)NC2 XEVFXAFXZZYFSX-UHFFFAOYSA-N 0.000 description 1
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- 101150096273 ADE2 gene Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 241000228431 Acremonium chrysogenum Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000589156 Agrobacterium rhizogenes Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- CKAJHWFHHFSCDT-WHFBIAKZSA-N Asp-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O CKAJHWFHHFSCDT-WHFBIAKZSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 102100029516 Basic salivary proline-rich protein 1 Human genes 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 102100037084 C4b-binding protein alpha chain Human genes 0.000 description 1
- 241000222128 Candida maltosa Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 101800005309 Carboxy-terminal peptide Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010048964 Carotid artery occlusion Diseases 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108700029231 Developmental Genes Proteins 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 1
- 102100036509 Erythropoietin receptor Human genes 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010069049 Gastrointestinal viral infection Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 102000000340 Glucosyltransferases Human genes 0.000 description 1
- 108010055629 Glucosyltransferases Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 1
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 1
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 1
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 1
- 102100020948 Growth hormone receptor Human genes 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 1
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 108010019494 Histatins Proteins 0.000 description 1
- 102000006492 Histatins Human genes 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101001125486 Homo sapiens Basic salivary proline-rich protein 1 Proteins 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 101001093736 Homo sapiens Polymeric immunoglobulin receptor Proteins 0.000 description 1
- 101000741885 Homo sapiens Protection of telomeres protein 1 Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- YZJSUQQZGCHHNQ-UHFFFAOYSA-N Homoglutamine Chemical compound OC(=O)C(N)CCCC(N)=O YZJSUQQZGCHHNQ-UHFFFAOYSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 241000209027 Ilex aquifolium Species 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010060231 Insect Proteins Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010038452 Interleukin-3 Receptors Proteins 0.000 description 1
- 102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 1
- KKJQZEWNZXRJFG-UHFFFAOYSA-N L-trans-4-Methyl-2-pyrrolidinecarboxylic acid Chemical compound CC1CNC(C(O)=O)C1 KKJQZEWNZXRJFG-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102100038609 Lactoperoxidase Human genes 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 101100243377 Mus musculus Pepd gene Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- BDFNAGOUUFOPSP-UHFFFAOYSA-N Nasvin Natural products O1C2=C(Cl)C(O)=C(Cl)C(C)=C2C(=O)OC2=C1C(C(C)=CC)=C(Cl)C(O)=C2CCCC BDFNAGOUUFOPSP-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 101150029183 PEP4 gene Proteins 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710136733 Proline-rich protein Proteins 0.000 description 1
- 102100038745 Protection of telomeres protein 1 Human genes 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108010019653 Pwo polymerase Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
- 240000005481 Salvia hispanica Species 0.000 description 1
- 235000001498 Salvia hispanica Nutrition 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108010068542 Somatotropin Receptors Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 102100028082 Tapasin Human genes 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108090000253 Thyrotropin Receptors Proteins 0.000 description 1
- 102100029337 Thyrotropin receptor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 244000301083 Ustilago maydis Species 0.000 description 1
- 235000015919 Ustilago maydis Nutrition 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
- PCBMGUSDYHYVBQ-SOOFDHNKSA-N [4-amino-2-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazol-5-yl]phosphonic acid Chemical compound P(=O)(O)(O)C=1N=C(NC1N)C1[C@H](O)[C@H](O)[C@H](O1)CO PCBMGUSDYHYVBQ-SOOFDHNKSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 108700023471 alginate-polylysine-alginate Proteins 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000689 aminoacylating effect Effects 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000009141 biological interaction Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000007816 calorimetric assay Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 210000000803 cardiac myoblast Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000012578 cell culture reagent Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000014167 chia Nutrition 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 150000002061 ecdysteroids Chemical class 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000002003 electron diffraction Methods 0.000 description 1
- 238000013171 endarterectomy Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007247 enzymatic mechanism Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000010228 ex vivo assay Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000012254 genetic linkage analysis Methods 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- MWFRVMDVLYIXJF-BYPYZUCNSA-N hydroxyethylcysteine Chemical compound OC(=O)[C@@H](N)CSCCO MWFRVMDVLYIXJF-BYPYZUCNSA-N 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 230000001184 hypocalcaemic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000004001 inositols Chemical class 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- GKOZUEZYRPOHIO-IGMARMGPSA-N iridium-192 Chemical compound [192Ir] GKOZUEZYRPOHIO-IGMARMGPSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000021231 nutrient uptake Nutrition 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000005222 photoaffinity labeling Methods 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 238000002805 secondary assay Methods 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000004683 skeletal myoblast Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 108010018381 streptavidin-binding peptide Proteins 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000007474 system interaction Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 108010059434 tapasin Proteins 0.000 description 1
- NPDBDJFLKKQMCM-UHFFFAOYSA-N tert-butylglycine Chemical compound CC(C)(C)C(N)C(O)=O NPDBDJFLKKQMCM-UHFFFAOYSA-N 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 108010055094 transporter associated with antigen processing (TAP) Proteins 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000013026 undiluted sample Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Definitions
- MHC major histocampatability complex
- ICAM-1 lymphocyte adhesion molecules
- Fc receptors T-cell CD8, CD28, and the like
- the isolated polynucleotide disclosed above comprises nucleotide 1 to nucleotide 597 of SEQ ID NO: 3.
- the isolated polynucleotide disclosed above consists of a sequence of amino acid residues an amino acid sequence selected from the group consisting of: (a) the amino acid sequence as shown in SEQ ID NO: 2 from residue number 18 (lie), to residue number 108 (Gly) ; (b) the amino acid sequence as shown in SEQ ID NO: 2 from amino acid number 18 (He) to amino acid number 125 (Pro) ; (c) the amino acid sequence as shown in SEQ ID NO: 2 from amino acid number 18 (He) to amino acid number 156 (Gin) ; (d) the amino acid sequence as shown in SEQ ID NO: 2 from amino acid number 18 (He) to amino acid number 199 (Gly) ; and (e) the amino acid sequence as shown in SEQ ID NO: 2 from amino acid number 1 (Met) to amino acid number 199 (Gly) .
- the present invention provides a method of producing a zsig57 polypeptide comprising: culturing a cell as disclosed above; and isolating the zsig57 polypeptide produced by the cell.
- contig denotes a polynucleotide that has a contiguous stretch of identical or complementary sequence to another polynucleotide. Contiguous sequences are said to "overlap" a given stretch of polynucleotide sequence either in their entirety or along a partial stretch of the polynucleotide. For example, representative contigs to the polynucleotide sequence 5'- ATGGAGCTT-3' are 5' -AGCTTgagt-3' and 3' -tcgacTACC-5' .
- a "DNA segment” is a portion of a larger DNA molecule having specified attributes.
- a DNA segment encoding a specified polypeptide is a portion of a longer DNA molecule, such as a plasmid or plasmid fragment, that, when read from the 5' to the 3' direction, encodes the sequence of amino acids of the specified polypeptide .
- expression vector is used to denote a
- the highly conserved amino acids in the Ig- variable domain, transmembrane domain, or other regions of zsig57 can be used as a tool to identify new family members.
- reverse transcription-polymerase chain reaction RT-PCR
- highly degenerate primers designed from the zsig57 sequences are useful for this purpose. Designing and using such degenerate primers is readily performed by one of skill in the art.
- any X NNN One of ordinary skill in the art will appreciate that some ambiguity is introduced in determining a degenerate codon, representative of all possible codons encoding each amino acid.
- the degenerate codon for serine can, in some circumstances, encode arginine (AGR)
- the degenerate codon for arginine (MGN) can, in some circumstances, encode serine (AGY) .
- some polynucleotides encompassed by the degenerate sequence may encode variant amino acid sequences, but one of ordinary skill in the art can easily identify such variant sequences by reference to the amino acid sequence of SEQ ID NO: 2. Variant sequences can be readily tested for functionality as described herein.
- preferential codon sequences into recombinant DNA can, for example, enhance production of the protein by making protein translation more efficient within a particular cell type or species. Therefore, the degenerate codon sequence disclosed in SEQ ID NO: 3 serves as a template for optimizing expression of polynucleotides in various cell types and species commonly used in the art and disclosed herein. Sequences containing preferential codons can be tested and optimized for expression in various species, and tested for functionality as disclosed herein.
- Double-stranded constructs are sequentially linked to one another to form the entire gene sequence and the sequence is verified by DNA sequence analysis. See Glick and Pasternak, Molecular Biotechnology, Principles & Applications of Recombinant DNA, (ASM Press, Washington, D.C. 1994); Itakura et al . , Annu. Rev. Biochem. 53 : 323-56, 1984 and Climie et al., Proc. Natl. Acad. Sci. USA 82:633-7, 1990.
- the present invention further provides counterpart polypeptides and polynucleotides from other species (orthologs) .
- species include, but are not limited to mammalian, avian, amphibian, reptile, fish, insect and other vertebrate and invertebrate species .
- zsig57 polypeptides from other mammalian species, including murine, porcine, ovine, bovine, canine, feline, equine, and other primate polypeptides.
- Orthologs of human zsig57 can be cloned using information and compositions provided by the present invention in combination with conventional cloning techniques.
- the present invention also provides isolated zsig57 polypeptides that are substantially similar to the polypeptides of SEQ ID NO: 2 and their orthologs.
- substantially similar is used herein to denote polypeptides having 70%, preferably 80%, more preferably at least 85%, sequence identity to the sequences shown in SEQ ID NO: 2 or their orthologs. Such polypeptides will more preferably be at least 90% identical, and most preferably 95% or more identical to SEQ ID NO:2 or its orthologs.) Percent sequence identity is determined by conventional methods. See, for example, Altschul et al., Bull. Math. Bio. £8: 603-16, 1986 and Henikoff and
- Sequence identity of polynucleotide molecules is determined by similar methods using a ratio as disclosed above .
- FASTA can also be used to determine the sequence identity of nucleic acid molecules using a ratio as disclosed above.
- the ktup value can range between one to six, preferably from three to six, most preferably three, with other parameters set as default.
- the BLOSUM62 table (Table 3) is an amino acid substitution matrix derived from about 2,000 local multiple alignments of protein sequence segments, representing highly conserved regions of more than 500 groups of related proteins (Henikoff and Henikoff, Proc . Na t ' l Acad. Sci . USA 59:10915 (1992)). Accordingly, the BLOSUM62 substitution frequencies can be used to define conservative amino acid substitutions that may be introduced into the amino acid sequences of the present invention.
- conservative amino acid substitution preferably refers to a substitution represented by a BLOSUM62 value of greater than -1.
- an amino acid substitution is conservative if the substitution is characterized by a BLOSUM62 value of 0, 1, 2, or 3.
- preferred conservative amino acid substitutions are characterized by a BLOSUM62 value of at least 1 (e.g., 1, 2 or 3), while more preferred conservative amino acid substitutions are characterized by a BLOSUM62 value of at least 2 (e.g., 2 or 3) .
- a zsig57 polypeptide or protein could be targeted to a predetermined cell type by fusing a zsig57 polypeptide to a ligand that specifically binds to a receptor on the surface of the target cell.
- polypeptides and proteins can be targeted for therapeutic or diagnostic purposes.
- a zsig57 polypeptide can be fused to two or more moieties, such as an affinity tag for purification and a targeting domain.
- Polypeptide fusions can also comprise one or more cleavage sites, particularly between domains. See, Tuan et al . , Connective Tissue Research 3_4:l-9, 1996.
- the proteins of the present invention can also comprise non-naturally occurring amino acid residues.
- Non-naturally occurring amino acids include, without limitation, trans-3-methylproline, 2, 4-methanoproline, cis-4-hydroxyproline, trans-4-hydroxyproline, N- methylglycine, allo-threonine, methylthreonine, hydroxyethylcysteine, hydroxyethylhomocysteine, nitroglutamine, homoglutamine, pipecolic acid, thiazolidine carboxylic acid, dehydroproline, 3- and 4- methylproline, 3, 3-dimethylproline, tert-leucine, norvaline, 2-azaphenylalanine, 3-azaphenylalanine, 4- azaphenylalanine, and 4-fluorophenylalanine .
- a limited number of non-conservative amino acids, amino acids that are not encoded by the genetic code, non-naturally occurring amino acids, and unnatural amino acids can be substituted for zsig57 amino acid residues .
- the identities of essential amino acids can also be inferred from analysis of homologies with related proteins such as the human CMRF35.Multiple amino acid substitutions can be made and tested using known methods of mutagenesis and screening, such as those disclosed by Reidhaar-Olson and Sauer (Science 241 :53-7, 1988) or Bowie and Sauer (Proc. Natl. Acad. Sci. USA 86:2152-6, 1989) . Briefly, these authors disclose methods for simultaneously randomizing two or more positions in a polypeptide, selecting for functional polypeptide, and then sequencing the mutagenized polypeptides to determine the spectrum of allowable substitutions at each position. Other methods that can be used include phage display (e.g., Lowman et al., Biochem.
- Mutagenesis methods as disclosed herein can be combined with high-throughput, automated screening methods to detect activity of cloned, mutagenized polypeptides in host cells.
- Mutagenized DNA molecules that encode active polypeptides e.g., IgA binding activity, or cAMP suppression as described herein
- IgA binding activity e.g., IgA binding activity, or cAMP suppression as described herein
- These methods allow the rapid determination of the importance of individual amino acid residues in a polypeptide of interest, and can be applied to polypeptides of unknown structure.
- any zsig57 polypeptide including variants and fusion proteins
- one of ordinary skill in the art can readily generate a fully degenerate polynucleotide sequence encoding that variant using the information set forth in Tables 1 and 2 above.
- Secretory signal sequences are commonly positioned 5 ' to the DNA sequence encoding the polypeptide of interest, although certain secretory signal sequences may be positioned elsewhere in the DNA sequence of interest (see, e.g., Welch et al . , U.S. Patent No. 5,037,743; Holland et al . , U.S. Patent No. 5,143,830).
- the secretory signal sequence contained in the polypeptides of the present invention is used to direct other polypeptides into the secretory pathway.
- the present invention provides for such fusion polypeptides.
- a signal fusion polypeptide can be made wherein a secretory signal sequence that encodes a signal peptide from amino acids 12 (Met) to 15 (Gly) of SEQ ID NO: 2 is operably linked to another DNA segment encoding a polypeptide using methods known in the art and disclosed herein.
- the secretory signal sequence contained in the fusion polypeptides of the present invention is preferably fused amino-terminally to an additional peptide to direct the additional peptide into the secretory pathway.
- Such constructs have numerous applications known in the art. For example, these novel secretory signal sequence fusion constructs can direct the secretion of an active component of a normally non-secreted protein. Such fusions can be used in vivo or in vi tro to direct peptides through the secretory pathway.
- suitable cell lines include but are not limited to intestinal cell lines, osteoblast, osteoclast, hematopoietic cell lines, and leukocyte cell lines.
- strong transcription promoters are preferred, such as promoters from SV-40 or cytomegalovirus . See, e.g., U.S. Patent No. 4,956,288.
- suitable promoters include those from metallothionein genes (U.S. Patent Nos. 4,579,821 and 4,601,978) and the adenovirus major late promoter .
- Selection systems can also be used to increase the expression level of the gene of interest, a process referred to as "amplification.” Amplification is carried out by culturing transfectants in the presence of a low level of the selective agent and then increasing the amount of selective agent to select for cells that produce high levels of the products of the introduced genes.
- a preferred amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate .
- Other drug resistance genes e.g. hygromycin resistance, multi-drug resistance, puromycin acetyltransferase
- hygromycin resistance e.g. hygromycin resistance, multi-drug resistance, puromycin acetyltransferase
- Alternative markers that introduce an altered phenotype such as green fluorescent protein, or cell surface proteins such as CD4, CD8, Class I MHC, placental alkaline phosphatase can be used to sort transfected cells from untransfected cells by such means as FACS sorting or magnetic bead separation technology.
- This system which utilizes transfer vectors, is sold in the Bac-to-BacTM kit (Life Technologies, Rockville, MD) .
- This system utilizes a transfer vector, pFastBaclTM (Life Technologies) containing a Tn7 transposon to move the DNA encoding the zsig57 polypeptide into a baculovirus genome maintained in E. coli as a large plasmid called a "bac id.”
- the pFastBaclTM transfer vector utilizes the AcNPV polyhedrin promoter to drive the expression of the gene of interest, in this case zsig57.
- pFastBaclTM can be modified to a considerable degree.
- transfer vectors can be constructed which replace the native zsig57 secretory signal sequences with secretory signal sequences derived from insect proteins.
- a secretory signal sequence from Ecdysteroid Glucosyltransferase (EGT) , honey bee Melittin (Invitrogen, Carlsbad, CA) , or baculovirus gp67 (PharMingen, San Diego, CA) can be used in constructs to replace the native zsig57 secretory signal sequence.
- Fungal cells including yeast cells, can also be used within the present invention.
- Yeast species of particular interest in this regard include Saccharomyces cerevisiae, Pichia pastoris, and Pichia methanolica .
- Methods for transforming S . cerevisiae cells with exogenous DNA and producing recombinant polypeptides therefrom are disclosed by, for example, Kawasaki, U.S. Patent No. 4,599,311; Kawasaki et al., U.S. Patent No. 4,931,373; Brake, U.S. Patent No. 4,870,008; Welch et al., U.S. Patent No. 5,037,743; and Murray et al., U.S. Patent No. 4,845,075.
- Pichia methanolica as host for the production of recombinant proteins is disclosed in WIPO Publications WO 97/17450, WO 97/17451, WO 98/02536, and WO 98/02565.
- DNA molecules for use in transforming P. methanolica will commonly be prepared as double-stranded, circular plasmids, which are preferably linearized prior to transformation.
- the promoter and terminator in the plasmid be that of a P. methanolica gene, such as a P. methanolica alcohol utilization gene (AUG1 or AUG2) .
- DHAS dihydroxyacetone synthase
- FMD formate dehydrogenase
- CAT catalase
- a preferred selectable marker for use in Pichia methanolica is a P. methanolica ADE2 gene, which encodes phosphoribosyl-5-aminoimidazole carboxylase (AIRC; EC 4.1.1.21), which allows ade2 host cells to grow in the absence of adenine .
- host cells For large-scale, industrial processes where it is desirable to minimize the use of methanol, it is preferred to use host cells in which both methanol utilization genes ⁇ AUG1 and AUG2) are deleted. For production of secreted proteins, host cells deficient in vacuolar protease genes [ PEP4 and PRB1 ) are preferred. Electroporation is used to facilitate the introduction of a plasmid containing DNA encoding a polypeptide of interest into P. methanolica cells. It is preferred to transform P.
- methanolica is YEPD (2% D-glucose, 2% BactoTM Peptone (Difco Laboratories, Detroit, MI) , 1% BactoTM yeast extract (Difco Laboratories), 0.004% adenine and 0.006% L-leucine) .
- the cells are lysed, and the granules are recovered and denatured using, for example, guanidine isothiocyanate or urea.
- the denatured polypeptide can then be refolded and dimerized by diluting the denaturant, such as by dialysis against a solution of urea and a combination of reduced and oxidized glutathione, followed by dialysis against a buffered saline solution.
- the polypeptide can be recovered from the periplasmic space in a soluble and functional form by disrupting the cells (by, for example, sonication or osmotic shock) to release the contents of the periplasmic space and recovering the protein, thereby obviating the need for denaturation and refolding.
- Transformed or transfected host cells are cultured according to conventional procedures in a culture medium containing nutrients and other components required for the growth of the chosen host cells.
- suitable media including defined media and complex media, are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins and minerals. Media can also contain such components as growth factors or serum, as required.
- the growth medium will generally select for cells containing the exogenously added DNA by, for example, drug selection or deficiency in an essential nutrient which is complemented by the selectable marker carried on the expression vector or co- transfected into the host cell.
- Protein purification methods include, fractionation of samples by ammonium sulfate precipitation and acid or chaotrope extraction. Exemplary purification steps may include hydroxyapatite, size exclusion, FPLC and reverse-phase high performance liquid chromatography . Suitable chromatographic media include derivatized dextrans, agarose, cellulose, polyacrylamide, specialty silicas, and the like. PEI, DEAE, QAE and Q derivatives are preferred.
- Exemplary chromatographic media include those media derivatized with phenyl, butyl, or octyl groups, such as Phenyl-Sepharose FF (Pharmacia), Toyopearl butyl 650 (Toso Haas, Montgomeryville, PA) , Octyl- Sepharose (Pharmacia) and the like; or polyacrylic resins, such as Amberchrom CG 71 (Toso Haas) and the like.
- Suitable solid supports include glass beads, silica-based resins, cellulosic resins, agarose beads, cross-linked agarose beads, polystyrene beads, cross-linked polyacrylamide resins and the like that are insoluble under the conditions in which they are to be used. These supports may be modified with reactive groups that allow attachment of proteins by amino groups, carboxyl groups, sulfhydryl groups, hydroxyl groups and/or carbohydrate moieties.
- Examples of coupling chemistries include cyanogen bromide activation, N-hydroxysuccinimide activation, epoxide activation, sulfhydryl activation, hydrazide activation, and carboxyl and amino derivatives for carbodiimide coupling chemistries .
- These and other solid media are well known and widely used in the art, and are available from commercial suppliers.
- Methods for binding receptor polypeptides to support media are well known in the art. Selection of a particular method is a matter of routine design and is determined in part by the properties of the chosen support. See, for example, Affinity Chromatography : Principles & Methods, Pharmacia LKB Biotechnology, Uppsala, Sweden, 1988.
- the polypeptides of the present invention can be isolated by exploitation of their biochemical, structural, and biological properties.
- immobilized metal ion adsorption (IMAC) chromatography can be used to purify histidine-rich proteins, including those comprising polyhistidine tags. Briefly, a gel is first charged with divalent metal ions to form a chelate (Sulkowski, Trends in Biochem. 3 : 1-1 , 1985). Histidine-rich proteins will be adsorbed to this matrix with differing affinities, depending upon the metal ion used, and will be eluted by competitive elution, lowering the pH, or use of strong chelating agents.
- IMAC immobilized metal ion adsorption
- maltose-binding protein e.g., maltose-binding protein, an immunoglobulin domain
- an immunoglobulin domain may be constructed to facilitate purification.
- the activity of the zsig57 polypeptides of the present invention can be measured by their ability to bind Ig.
- the IgA binding assay for the secretory component of plgR is known in the art and can be applied to the polypeptides of the present invention. See, Rindisbacher, L., et al . , J. Biol. Chem., 270: 14220-14228, 1995.
- zsig57 polypeptides of the present invention can be used to study pancreatic cell proliferation or differentiation.
- Such methods of the present invention generally comprise incubating ⁇ cells, ⁇ cells, ⁇ cells, F cells and acinar cells in the presence and absence of zsig57 polypeptide, monoclonal antibody, agonist . or antagonist thereof and observing changes in islet cell proliferation or differentiation.
- a further aspect of the invention provides a method for studying insulin.
- Such methods of the present invention comprise incubating adipocytes in a culture medium comprising zsig57 polypeptide, monoclonal antibody, agonist or antagonist thereof ⁇ insulin and observing changes in adipocyte protein secretion or differentiation.
- the present invention also provides methods of studying mammalian cellular metabolism.
- Such methods of the present invention comprise incubating cells to be studied, for example, human vascular endothelial cells, ⁇ zsig57 polypeptide, monoclonal antibody, agonist or antagonist thereof and observing changes in adipogenesis, gluconeogenesis, glycogenolysis, lipogenesis, glucose uptake, or the like.
- zsig57 polypeptides, agonists or antagonists thereof can be therapeutically useful for promoting wound healing, for example, in the intestine.
- agonists or antagonists of the present invention such zsig57 polypeptides, agonists or antagonists are evaluated with respect to their ability to facilitate wound healing according to procedures known in the art.
- zsig57 polypeptide performance in this regard can be compared to growth factors, such as EGF, NGF, TGF- ⁇ , TGF- ⁇ , insulin, IGF-I, IGF-II, fibroblast growth factor (FGF) and the like.
- zsig57 polypeptides or agonists or antagonists thereof can be evaluated in combination with one or more growth factors to identify synergistic effects.
- Receptor activation can be detected by: (1) measurement of adenylate cyclase activity (Salomon et al., Anal. Biochem. 58 ⁇ :541-48, 1974; Alvarez and Daniels, Anal . Biochem. 187 : 98-103, 1990); (2) measurement of change in intracellular cAMP levels using conventional radioimmunoassay methods (Steiner et al . , J. Biol. Chem. 247:1106-13, 1972; Harper and Brooker, J. Cyc . Nucl . Res. 1:207-18, 1975); or (3) through use of a cAMP scintillation proximity assay (SPA) method (Amersham Corp., Arlington Heights, IL) . While these methods provide sensitivity and accuracy, they involve considerable sample processing prior to assay, are time consuming, involve the use of radioisotopes, and would be cumbersome for large scale screening assays.
- SPA cAMP scintillation proximity assay
- An alternative assay system involves selection of polypeptides that are able to induce expression of a cyclic AMP response element (CRE) -luciferase reporter gene, as a consequence of elevated cAMP levels, in cells expressing a calcitonin receptor, but not in cells lacking calcitonin receptor expression, as described in U.S. patent No. 5,622,839, U.S. Patent No. 5,674,689, and U.S. patent No. 5, 674, 981.
- CRE cyclic AMP response element
- zsig57 polypeptides that interact with the calcitonin receptor.
- these models can be used to test effects of zsig57 on bone other than through the calcitonin receptor.
- the hypocalcemic rat or mouse model can be used to determine the effect on serum calcium
- the ovariectomized rat or mouse can be used as a model system for osteoporosis. Bone changes seen in these models and in humans during the early stages of estrogen deficiency are qualitatively similar.
- Calcitonin has been shown to be an effective agent for the prevention of bone loss in ovariectomized women and rats (Mazzuoli et al., Calcif. Tissue Int.
- Biologically active zsig57 polypeptides of the present invention that interact with the calcitonin receptor, or exert other effects on bone, are therefore contemplated to be advantageous for use in therapeutic applications for which calcitonin is useful.
- Such applications for example, are in the treatment of osteoporosis, Paget ' s disease, hyperparathyroidism, osteomalacia, idiopathic hypercalcemia of infancy and other conditions.
- Additional applications are to inhibit gastric secretion in the treatment of acute pancreatitis and gastrointestinal disorders, and uses as analgesics, in particular for bone pain.
- In vivo assays for measuring changes in bone formation rates include performing bone histology (see, Recker, R., eds.
- An exemplary ex vivo assay for measuring changes in bone formation is a calavarial assay
- polypeptides of the present invention can be assayed and used for their ability to modify inflammation. Methods to determine proinflammatory and antiinflammatory qualities of zsig57 are known in the art and discussed herein.
- Proteins of the present invention are useful for example, in treating gastrointestinal, lymphoid, inflammatory, pancreatic, blood or bone disorders, can be measured in vitro using cultured cells or in vivo by administering molecules of the claimed invention to the appropriate animal model.
- host cells expressing a secreted form of zsig57 polypeptide can be embedded in an alginate environment and injected (implanted) into recipient animals.
- Alginate-poly-L- lysine microencapsulation, permselective membrane encapsulation and diffusion chambers are a means to entrap transfected mammalian cells or primary mammalian cells.
- Alginate threads provide a simple and quick means for generating embedded cells.
- the materials needed to generate the alginate threads are known in the art. In an exemplary procedure, 3% alginate is prepared in sterile H2O, and sterile filtered. Just prior to preparation of alginate threads, the alginate solution is again filtered. An approximately 50% cell suspension (containing about 5 x 10 ⁇ to about 5 x
- the extruded thread is then transferred into a solution of 50 mM CaCl2, and then into a solution of 25 mM CaCl2.
- the thread is then rinsed with deionized water before coating the thread by incubating in a 0.01% solution of poly-L-lysine .
- the thread is rinsed with Lactated Ringer's Solution and drawn from solution into a syringe barrel (without needle) .
- a large bore needle is then attached to the syringe, and the thread is intraperitoneally injected into a recipient in a minimal volume of the Lactated Ringer's Solution.
- An alternative in vivo approach for assaying proteins of the present invention involves viral delivery systems.
- viruses for this purpose include adenovirus, herpesvirus, retroviruses, vaccinia virus, and adeno-associated virus (AAV).
- Adenovirus a double- stranded DNA virus, is currently the best studied gene transfer vector for delivery of heterologous nucleic acid (for review, see T.C. Becker et al . , Meth. Cell Biol. £:161-89, 1994; and J.T. Douglas and D.T. Curiel, Science & Medicine £:44-53, 1997).
- adenovirus can accommodate relatively large DNA inserts; (ii) can be grown to high- titer; (iii) infect a broad range of mammalian cell types; and (iv) can be used with many different promoters including ubiquitous, tissue specific, and regulatable promoters. Also, because adenoviruses are stable in the bloodstream, they can be administered by intravenous injection.
- the host's tissue e.g., liver
- the host's tissue will express and process (and, if a secretory signal sequence is present, secrete) the heterologous protein.
- Secreted proteins will enter the circulation in the highly vascularized liver, and effects on the infected animal can be determined.
- an expressed, secreted heterologous protein can be repeatedly isolated from the cell culture supernatant, lysate, or membrane fractions depending on the disposition of the expressed protein in the cell. Within the infected 293 cell production protocol, non-secreted proteins may also be effectively obtained.
- the activity of zsig57 polypeptide can be measured by a silicon-based biosensor microphysiometer which measures the extracellular acidification rate or proton excretion associated with receptor binding and subsequent physiologic cellular responses.
- An exemplary device is the CytosensorTM Microphysiometer manufactured by Molecular Devices, Sunnyvale, CA.
- ZSIG57-responsive eukaryotic cells comprise cells into which a receptor for zsig57 has been transfected creating a cell that is responsive to zsig57; or cells naturally responsive to zsig57 such as cells derived from small intestine, PBLs, or bone marrow tissue. Differences, measured by a change, for example, an increase or diminution in extracellular acidification, in the response of cells exposed to zsig57 polypeptide, relative to a control not exposed to zsig57, are a direct measurement of zsig57-modulated cellular responses. Moreover, such zsig57-modulated responses can be assayed under a variety of stimuli.
- zsig57 can be used to identify cells, tissues, or cell lines which respond to a zsig57- stimulated pathway.
- the microphysiometer, described above can be used to rapidly identify ligand-responsive cells, such as cells responsive to zsig57 of the present invention.
- Cells can be cultured in the presence or absence of zsig57 polypeptide. Those cells which elicit a measurable change in extracellular acidification in the presence of zsig57 are responsive to zsig57.
- Such cell lines can be used to identify antagonists and agonists of zsig57 polypeptide as described above.
- agonists including the natural ligand/ substrate/ cofactor/ etc.
- antagonists have enormous potential in both in vi tro and in vivo applications.
- Compounds identified as zsig57 agonists are useful for stimulating cell growth or signal transduction in vi tro and in vivo .
- zsig57 and zsig57 agonist and antagonist compounds are useful as components of defined cell culture media, and can be used alone or in combination with other cytokines and hormones to replace serum that is commonly used in cell culture. Agonists are thus useful in specifically promoting the growth and/or development of cells in culture.
- Antagonists are also useful as research reagents for characterizing sites of ligand-receptor interaction.
- Inhibitors of zsig57 activity include anti-zsig57 antibodies and soluble proteins which bind zsig57 polypeptide, as well as other peptidic and non- peptidic agents (including ribozymes) .
- Zsig57 can be used to identify inhibitors
- DNA response elements can include, but are not limited to, cyclic AMP response elements (CRE) , hormone response elements (HRE) insulin response element (IRE) (Nasrin et al., Proc. Natl. Acad. Sci. USA 81_: 5213-1 , 1990) and serum response elements (SRE) (Shaw et al . Cell 56: 563-72, 1989).
- Cyclic AMP response elements are reviewed in Roestler et al., J. Biol. Chem. 263 (19):9063-6; 1988 and Habener, Molec. Endocrinol. £ (8):1087-94; 1990.
- Hormone response elements are reviewed in Beato, Cell 5_6:335-44; 1989.
- Candidate compounds, solutions, mixtures or extracts are tested for the ability to inhibit the activity of zsig57 on the target cells as evidenced by a decrease in zsig57 stimulation of reporter gene expression. Assays of this type will detect compounds that directly block zsig57 binding to cell-surface receptors, as well as compounds that block processes in the cellular pathway subsequent to receptor-ligand binding. In the alternative, compounds or other samples can be tested for direct blocking of zsig57 binding to receptor using zsig57 tagged with a detectable label (e.g., 125 I, biotin, horseradish peroxidase, FITC, and the like) .
- a detectable label e.g., 125 I, biotin, horseradish peroxidase, FITC, and the like
- Receptors used within binding assays may be cellular receptors or isolated, immobilized receptors.
- a zsig57 polypeptide can be expressed as a fusion with an immunoglobulin heavy chain constant region, typically an F c fragment, which contains two constant region domains and lacks the variable region.
- an immunoglobulin heavy chain constant region typically an F c fragment
- Methods for preparing such fusions are disclosed in U.S. Patents Nos. 5,155,027 and 5,567,584.
- Such fusions are typically secreted as multimeric molecules wherein the Fc portions are disulfide bonded to each other and two non-Ig polypeptides are arrayed in closed proximity to each other. Fusions of this type can be used to affinity purify ligand, as an in vitro assay tool, or zsig57 antagonist.
- the chimeras are bound to a support via the F c region and used in an ELISA format .
- a zsig57 polypeptide can also be used for purification of ligand or polypeptides to which it binds.
- the zsig57 polypeptide is immobilized on a solid support, such as- beads of agarose, cross-linked agarose, glass, cellulosic resins, silica-based resins, polystyrene, cross-linked polyacrylamide, or like materials that are stable under the conditions of use.
- Methods for linking polypeptides to solid supports are known in the art, and include amine chemistry, cyanogen bromide activation, N- hydroxysuccinimide activation, epoxide activation, sulfhydryl activation, and hydrazide activation.
- the resulting medium will generally be configured in the form of a column, and fluids containing ligand are passed through the column one or more times to allow ligand to bind to the receptor zsig57 polypeptide.
- the ligand is then eluted using changes in salt concentration, chaotropic agents (guanidine HC1), or pH to disrupt ligand-receptor binding.
- a receptor, antibody, member or fragment is covalently attached, using amine or sulfhydryl chemistry, to dextran fibers that are attached to gold film within the flow cell.
- a test sample is passed through the cell. If a ligand, epitope, or opposite member of the complement/anti-complement pair is present in the sample, it will bind to the immobilized receptor, antibody or member, respectively, causing a change in the refractive index of the medium, which is detected as a change in surface plasmon resonance of the gold film.
- This system allows the determination of on- and off-rates, from which binding affinity can be calculated, and assessment of stoichiometry of binding.
- Ligand-binding receptor polypeptides can also be used within other assay systems known in the art.
- Such systems include Scatchard analysis for determination of binding affinity (see Scatchard, Ann. NY Acad. Sci. 51 : 660-72, 1949) and calorimetric assays (Cunningham et al . , Science 253 : 545-48, 1991; Cunningham et al . , Science 2£5:821-25, 1991) .
- Zsig57 polypeptides can also be used to prepare antibodies that bind to zsig57 epitopes, peptides or polypeptides.
- the zsig57 polypeptide or a fragment thereof serves as an antigen (immunogen) to inoculate an animal and elicit an immune response.
- antigenic, epitope-bearing polypeptides contain a sequence of at least 6, preferably at least 9, and more preferably at least 15 to about 30 contiguous amino acid residues of a zsig57 polypeptide (e.g., SEQ ID NO:2).
- Polypeptides comprising a larger portion of a zsig57 polypeptide, i.e., from 30 to 10 residues up to the entire length of the amino acid sequence are included.
- Antigens or immunogenic epitopes can also include attached tags, adjuvants and carriers, as described herein.
- Suitable antigens include the zsig57 polypeptide encoded by SEQ ID NO: 2 from amino acid number 16 (Gin) to amino acid number 199 (Gin) , or a contiguous 9 to 199 AA amino acid fragment thereof.
- Other suitable antigens include the Ig-variable domain, Ig-variable domain with additional amino acids up to acidic cleavage sites, cytoplasmic stub, and other domains of zsig57, described herein.
- hydrophilic peptides such as those predicted by one of skill in the art from a hydrophobicity plot (See Figure 2).
- Zsig57 hydrophilic peptides include peptides comprising amino acid sequences selected from the group consisting of: (1) amino acid number 96 (Glu) to amino acid number 101 (Glu) of SEQ ID NO:2; (2) amino acid number 124 (Pro) to amino acid number 129 (Glu) of SEQ ID NO: 2; (3) amino acid number 125 (Pro) to amino acid number 130 (Glu) of SEQ ID NO : 2 ; (4) amino acid number 185 (Arg) to amino acid number 190 (Glu) of SEQ ID NO:2; and (5) amino acid number 186 (Lys) to amino acid number 191 (Ser) of SEQ ID NO: 2.
- Antibodies from an immune response generated by inoculation of an animal with these antigens can be isolated and purified as described herein. Methods for preparing and isolating polyclonal and monoclonal antibodies are well known in the art. See, for example, Current Protocols in Immunology, Cooligan, et al . (eds.), National Institutes of Health, John Wiley and Sons, Inc., 1995; Sambrook et al . , Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, NY, 1989; and Hurrell, J. G. R. , Ed., Monoclonal Hybridoma Antibodies: Techniques and Applications, CRC Press, Inc., Boca Raton, FL, 1982.
- the polypeptide immunogen can be a full-length molecule or a portion thereof. If the polypeptide portion is "hapten-like", such portion can be advantageously joined or linked to a macromolecular carrier (such as keyhole limpet hemocyanin (KLH) , bovine serum albumin (BSA) or tetanus toxoid) for immunization.
- a macromolecular carrier such as keyhole limpet hemocyanin (KLH) , bovine serum albumin (BSA) or tetanus toxoid
- antibodies includes polyclonal antibodies, affinity-purified polyclonal antibodies, monoclonal antibodies, and antigen-binding fragments, such as F(ab')2 an ⁇ Fab proteolytic fragments. Genetically engineered intact antibodies or fragments, such as chimeric antibodies, Fv fragments, single chain antibodies and the like, as well as synthetic antigen- binding peptides and polypeptides, are also included.
- Non-human antibodies can be humanized by grafting non- human CDRs onto human framework and constant regions, or by incorporating the entire non-human variable domains (optionally "cloaking" them with a human-like surface by replacement of exposed residues, wherein the result is a "veneered” antibody). In some instances, humanized antibodies can retain non-human residues within the human variable region framework domains to enhance proper binding characteristics. Through humanizing antibodies, biological half-life can be increased, and the potential for adverse immune reactions upon administration to humans is reduced.
- Alternative techniques for generating or selecting antibodies useful herein include in vi tro exposure of lymphocytes to zsig57 protein or peptide, and selection of antibody display libraries in phage or similar vectors (for instance, through use of immobilized or labeled zsig57 protein or peptide) .
- Genes encoding polypeptides having potential zsig57 polypeptide binding domains can be obtained by screening random peptide libraries displayed on phage (phage display) or on bacteria-, such as E . coli .
- Nucleotide sequences encoding the polypeptides can be obtained in a number of ways, such as through random mutagenesis and random polynucleotide synthesis.
- Random peptide display libraries can be screened using the zsig57 sequences disclosed herein to identify proteins which bind to zsig57.
- These "binding proteins" which interact with zsig57 polypeptides can be used for tagging cells; for isolating homolog polypeptides by affinity purification; they can be directly or indirectly conjugated to drugs, toxins, radionuclides and the like.
- binding proteins can also be used in analytical methods such as for screening expression libraries and neutralizing activity.
- the binding proteins can also be used for diagnostic assays for determining circulating levels of polypeptides; for detecting or quantitating soluble polypeptides as marker of underlying pathology or disease.
- binding proteins can also act as zsig57 "antagonists" to block zsig57 binding and signal transduction in vitro and in vivo .
- human antibodies can be produced in transgenic, non-human animals that have been engineered to contain human immunoglobulin genes as disclosed in WIPO Publication WO 98/24893. It is preferred that the endogenous immunoglobulin genes in these animals be inactivated or eliminated, such as by homologous recombination .
- Antibodies are considered to be specifically binding if: 1) they exhibit a threshold level of binding activity, and 2) they do not significantly cross-react with related polypeptide molecules.
- a threshold level of binding is determined if anti-zsig57 antibodies herein bind to a zsig57 polypeptide, peptide or epitope with an affinity at least 10-fold greater than the binding affinity to control (non-zsig57) polypeptide. It is preferred that the antibodies exhibit a binding affinity
- K a 10 M or greater, preferably 10 M or greater, p _ 1 more preferably 10 M or greater, and most preferably 10 9 M-1 or greater.
- the binding affinity of an antibody can be readily determined by one of ordinary skill in the art, for example, by Scatchard analysis (Scatchard, G., Ann. NY Acad. Sci. 5£: 660-672, 1949) .
- anti-zsig57 antibodies do not significantly cross-react with related polypeptide molecules is shown, for example, by the antibody detecting zsig57 polypeptide but not known related polypeptides using a standard Western blot analysis (Ausubel et al . , ibid. ) .
- known related polypeptides are those disclosed in the prior art, such as known orthologs, and paralogs, and similar known members of a protein family, (e.g. CMRF35 and SC) . Screening can also be done using non-human zsig57, and zsig57 mutant polypeptides.
- antibodies can be "screened against" known related ⁇ polypeptides, to isolate a population that specifically binds to the zsig57 polypeptides.
- antibodies raised to zsig57 are adsorbed to related polypeptides adhered to insoluble matrix; antibodies specific to zsig57 will flow through the matrix under the proper buffer conditions. Screening allows isolation of polyclonal and monoclonal antibodies non- crossreactive to known closely related polypeptides (Antibodies: A Laboratory Manual, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988; Current Protocols in Immunology, Cooligan, et al . (eds.), National Institutes of Health, John Wiley and Sons, Inc., 1995).
- assays known to those skilled in the art can be utilized to detect antibodies which specifically bind to zsig57 proteins or polypeptides. Exemplary assays are described in detail in Antibodies: A Laboratory Manual, Harlow and Lane (Eds.), Cold Spring Harbor Laboratory Press, 1988. Representative examples of such assays include: concurrent immunoelectrophoresis, radioimmunoassay, radioimmuno-precipitation, enzyme-linked immunosorbent assay (ELISA) , dot blot or Western blot assay, inhibition or competition assay, and sandwich assay. In addition, antibodies can be screened for binding to wild-type versus mutant zsig57 protein or polypeptide .
- ELISA enzyme-linked immunosorbent assay
- Antibodies to zsig57 can be used for tagging cells that express zsig57; for isolating zsig57 by affinity purification; for diagnostic assays for determining circulating levels ozsig57 polypeptides; for detecting or quantitating soluble zsig57 polypeptides as marker of underlying pathology or disease.
- These binding polypeptides can also act as zsig57 "antagonists" to block zsig57 binding and signal transduction in vi tro and in vivo .
- These anti-zsig57 binding polypeptides would be useful for inhibiting zsig57 activity or protein-binding.
- Antibodies to zsig57 may be used for tagging cells that express zsig57; for isolating zsig57 by affinity purification; for diagnostic assays for determining circulating levels of zsig57 polypeptides; for detecting or quantitating soluble zsig57 as marker of underlying pathology or disease; in analytical methods employing FACS; for screening expression libraries; for generating anti-idiotypic antibodies; and as neutralizing antibodies or as antagonists to block zsig57 activity in vitro and in vivo .
- Polypeptides or antibodies can also be conjugated to cytotoxic drugs, such as adriamycin.
- cytotoxic drugs such as adriamycin.
- the detectable or cytotoxic molecule can be conjugated with a member of a complementary/ anticomplementary pair, where the other member is bound to the polypeptide or antibody portion.
- biotin/streptavidin is an exemplary complementary/ anticomplementary pair.
- polypeptide-toxin fusion proteins or antibody-toxin fusion proteins can be used for targeted cell or tissue inhibition or ablation (for instance, to treat cancer cells or tissues).
- a fusion protein including only the targeting domain may be suitable for directing a detectable molecule, a cytotoxic molecule or a complementary molecule to a cell or tissue type of interest.
- the domain only fusion protein includes a complementary molecule
- the anti- complementary molecule can be conjugated to a detectable or cytotoxic molecule.
- Such domain-complementary molecule fusion proteins thus represent a generic targeting vehicle for cell/tissue-specific delivery of generic anti- complementary-detectable/ cytotoxic molecule conjugates.
- zsig57-cytokine fusion proteins or antibody-cytokine fusion proteins can be used for enhancing in vivo killing of target tissues (for example, intestinal, lymphoid, blood and bone marrow cancers) , if the zsig57 polypeptide or anti-zsig57 antibody targets, for example, the hyperproliferative blood or bone marrow cell (See, generally, Hornick et al . , Blood 8_9:4437-47, 1997).
- target tissues for example, intestinal, lymphoid, blood and bone marrow cancers
- zsig57 polypeptide or anti-zsig57 antibody targets for example, the hyperproliferative blood or bone marrow cell (See, generally, Hornick et al . , Blood 8_9:4437-47, 1997).
- fusion proteins enable targeting of a cytokine to a desired site of action, thereby providing an elevated local concentration of cytokine.
- the zsig57 polypeptide or anti-zsig57 antibody targets vascular cells or tissues
- such polypeptide or antibody can be conjugated with a radionuclide, and particularly with a beta-emitting radionuclide, to reduce restenosis.
- a radionuclide and particularly with a beta-emitting radionuclide
- Such therapeutic approach poses less danger to clinicians who administer the radioactive therapy.
- iridium-192 impregnated ribbons placed into stented vessels of patients until the required radiation dose was delivered showed decreased tissue growth in the vessel and greater luminal diameter than the control group, which received placebo ribbons. Further, revascularisation and stent thrombosis were significantly lower in the treatment group. Similar results are predicted with targeting of a bioactive conjugate containing a radionuclide, as described herein.
- the bioactive polypeptide or antibody conjugates described herein can be delivered intravenously, intraarterially or intraductally, or can be introduced locally at the intended site of action.
- polypeptides, nucleic acid and/or antibodies of the present invention can be used in treatment of disorders associated with the immune system, gastrointestinal system, heart, inflammation, lymph system, bone marrow, blood and bones.
- the molecules of the present invention may used to modulate or to treat or prevent development of pathological conditions in such diverse tissue as small intestine and bone marrow.
- certain syndromes or diseases can be amenable to such diagnosis, treatment or prevention.
- polypeptides of the present invention can be used for their ability to modify inflammation.
- Methods to assess proinflammatory or antiinflammatory qualities of zsig57 are known in the art.
- suppression of cAMP production is an indication of anti-inflammatory effects of the plgR secretory component (SC) (Nihei, Y., et al., Arch. Dermatol. Res., 287:546-552, 1995).
- SC plgR secretory component
- Free SC component of the poly-IgR suppressed cAMP and inhibited ICAM and HLA-Dr induced by IFN- ⁇ in keratinocytes .
- free SC has been reported to inhibit P1A2 and is believed to act via the arachadonic acid antiinflammatory cascade.
- Zsig57 likewise can exhibit similar anti-inflammatory effects, and may exert these effects in tissues in which it is expressed.
- zsig57 is expressed in the small intestine, and can be useful in treatment of inflammatory bowel disease, diverticulitis, inflammation during and after intestinal surgery, and the like.
- zsig57, expressed in PBLs and bone marrow can have other antiinflammatory actions in heart, pelvic inflammatory disease, (PID) , psoriasis, arthritis, and other inflammatory diseases.
- PID pelvic inflammatory disease
- psoriasis psoriasis
- arthritis and other inflammatory diseases.
- zsig57 polypeptide As such, zsig57 polypeptide, or its antagonists, have potential uses in inflammatory diseases such as asthma and arthritis. For example, if zsig57 is proinflammatory antagonists would be valuable in asthma therapy or other anti-inflammatory therapies where migration of lymphocytes is damaging. Alternatively, zsig57 can have an inhibitory or competitive effect on inflammatory agents and may serve directly as an asthma therapeutic or anti-inflammatory. In addition, zsig57 can serve other important roles in lung function, for instance, bronchodilation, tissue elasticity, recruitment of lymphocytes in lung infection and damage. Assays to assess the activity of zsig57 in lung cells are discussed in Laberge, S. et al . , Am. J. Respir. Cell Mol. Biol.
- zsig57 may exhibit antiviral functions by inhibiting viral replication by specific signaling via it's receptor (s) on a host cell (e.g. T-cell) .
- Zsig57 may exhibit immune cell proliferative activity, as disclosed herein, and may stimulate the immune system to fight viral infections.
- zsig57 may bind CD4 or another lymphocyte receptor and exhibit antiviral effects, for example, against human immunodeficiency virus (HIV) or human T-cell lymphotropic virus (HTLV) .
- zsig57 polypeptide may compete for a viral receptor or co- receptor to block viral infection.
- Zsig57 may be given parentally to prevent viral infection or to reduce ongoing viral replication and re-infection (Gayowski, T. et al . , Transplantation 64:422-426, 1997).
- zsig57 may be used as. an antiviral therapeutic, for example, for viral leuke ias (HTLV) , AIDS (HIV) , or gastrointestinal viral infections caused by, for example, rotavirus, calicivirus
- the molecules of the present invention can be useful for proliferation of cardiac tissue cells, such as cardiac myocytes or myoblasts; skeletal myocytes or myoblasts and smooth muscle cells; chrondrocytes; endothelial cells; adipocytes and osteoblasts in vitro .
- cardiac tissue cells such as cardiac myocytes or myoblasts; skeletal myocytes or myoblasts and smooth muscle cells; chrondrocytes; endothelial cells; adipocytes and osteoblasts in vitro .
- molecules of the present invention are useful as components of defined cell culture media, and can be used alone or in combination with other cytokines and hormones to replace serum that is commonly used in cell culture.
- Molecules of the present invention are particularly useful in specifically promoting the growth and/or development of myocytes in culture, and may also prove useful in the study of cardiac myocyte hyperplasia and regeneration.
- polypeptides, nucleic acids and/or antibodies of the present invention can be used in treatment of disorders associated with myocardial infarction, congestive heart failure, hypertrophic cardiomyopathy and dilated cardiomyopathy .
- Molecules of the present invention may also be useful for limiting infarct size following a heart attack, aiding in recovery after heart transplantation, promoting angiogenesis and wound healing following angioplasty or endarterectomy, to develop coronary collateral circulation, for revascularization in the eye, for complications related to poor circulation such as diabetic foot ulcers, for stroke, following coronary reperfusion using pharmacologic methods, and other indications where angiogenesis is of benefit.
- Zsig57 induced coronary collateral development is measured in rabbits, dogs or pigs using models of chronic coronary occlusion (Landau et al . , Amer. Heart J. £9:924-931, 1995; Sellke et al . , Surgery 120 (2) .182-188, 1996; and Lazarous et al . , 1996, ibid. )
- Zsig57 efficacy for treating stroke is tested in vivo in rats, utilizing bilateral carotid artery occlusion and measuring histological changes, as well as maze performance (Gage et al., Neurobiol. Aging _9:645-655, 1988).
- zsig57 polypeptide is expressed in the small intestine.
- zsig57 polypeptide pharmaceutical compositions of the present invention can also be useful in prevention or treatment of digestive disorders in the GI tract, such as disorders associated with pathological secretory cell expansion or differentiation.
- Assays and animal models are known in the art for monitoring such expansion or differentiation and for evaluating zsig57 polypeptide, fragment, fusion protein, antibody, agonist or antagonist in the prevention or treatment thereof.
- trefoil factors in the intestine are known to be involved in mucosal stabilization in the gut and repair processes associated with acute injury, particularly epithelial restitution (Poulsom, R., Bail. Clin. Gastro., 10; 113-134, 1996; Sands, B.E., and Podolsky, D.K., Annu . Rev. Physiol., 58; 253-273, 1996.
- trefoil proteins appear to have a role in healing wounds caused by intestinal inflammatory diseases, and resisting microbial invasion via mucosal secretion involvement (Palut, A.G., New Eng . J. Med., 336; 5-6-507, 1997; Playford, R.J., J.
- Epidermal growth factor (EGF) receptor ligands may play a role in enhancing trefoil activity in the gut; however, repair of mucosal injury is not dependent in the main endogenous EGF receptor ligand in the gut, TNF-a, suggesting a role of other undiscovered ligands (Cook, G.A., et al., Am. Physiol. Soc, G1540-G1549, 1997).
- the zsig57 polypeptides can serve as such ligand, regulatory protein or other factor in the trefoil pathway, and hence play an important therapeutic role in diseases and injury associated with the gut and mucosal epithelium.
- zsig57 polypeptide is expressed in the bone marrow and PBLs and can exert its effects in the vital organs of the body. Activity of zsig57 expressed in PBLs and bone marrow be independent of gastrointestinal function.
- zsig57 polypeptide pharmaceutical compositions of the present invention can be useful in prevention or treatment of pancreatic disorders associated with pathological regulation of the expansion of neuroendocrine and exocrine cells in the pancreas, such as IDDM, pancreatic cancer, pathological regulation of blood glucose levels, insulin resistance or digestive function.
- the zsig57 polypeptide of the present invention may act in the neuroendocrine/exocrine cell fate decision pathway and is therefore capable of regulating the expansion of neuroendocrine and exocrine cells in the pancreas.
- One such regulatory use is that of islet cell regeneration.
- zsig57 polypeptide is a developmental gene involved in cell partitioning.
- Assays and animal models are known in the art for monitoring the exocrine/neuroendocrine cell lineage decision, for observing pancreatic cell balance and for evaluating zsig57 polypeptide, fragment, fusion protein, antibody, agonist or antagonist in the prevention or treatment of the conditions set forth above.
- Polynucleotides encoding zsig57 polypeptides are useful within gene therapy applications where it is desired to increase or inhibit zsig57 activity. If a mammal has a mutated or absent zsig57 gene, the zsig57 gene can be introduced into the cells of the mammal. In one embodiment, a gene encoding a zsig57 polypeptide is introduced in vivo in a viral vector.
- viral vectors include an attenuated or defective DNA virus, such as, but not limited to, herpes simplex virus (HSV) , papillomavirus, Epstein Barr virus (EBV) , adenovirus, adeno-associated virus (AAV), and the like.
- Defective viruses which entirely or almost entirely lack viral genes, are preferred.
- a defective virus is not infective after introduction into a cell.
- Use of defective viral vectors allows for administration to cells in a specific, localized area, without concern that virus will be produced and the vector transferred to other cells via infection.
- Examples of particular vectors include, but are not limited to, a defective herpes simplex virus 1 (HSV1) vector (Kaplitt et al . , Molec. Cell. Neurosci. .2:320-30, 1991); an attenuated adenovirus vector, such as the vector described by Stratford-Perricaudet et al . , J. Clin. Invest.
- HSV1 herpes simplex virus 1
- a zsig57 gene can be introduced in a retroviral vector, e.g., as described in Anderson et al . , U.S. Patent No. 5,399,346; Mann et al . Cell 33:153, 1983; Te in et al . , U.S. Patent No. 4,650,764; Temin et al . , U.S. Patent No.
- the vector can be introduced by lipofection in vivo using liposomes. Synthetic cationic lipids can be used to prepare liposomes for in vivo transfection of a gene encoding a marker (Feigner et al . , Proc. Natl. Acad. Sci.
- lipofection to introduce exogenous genes into specific organs in vivo has certain practical advantages.
- Molecular targeting of liposomes to specific cells represents one area of benefit. More particularly, directing transfection to particular cells represents one area of benefit. For instance, directing transfection to particular cell types would be particularly advantageous in a tissue with cellular heterogeneity, such as the pancreas, liver, kidney, and brain.
- Lipids can be chemically coupled to other molecules for the purpose of targeting.
- Targeted peptides e.g., hormones or neurotransmitters
- proteins such as antibodies
- non-peptide molecules can be coupled to liposomes chemically.
- DNA vectors for gene therapy can be introduced into the desired .host cells by methods known in the art, e.g., transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun or use of a DNA vector transporter. See, e.g., Wu et al . , J. Biol. Chem. 267:963-7, 1992; Wu et al . , J. Biol. Chem. 263:14621-4, 1988.
- zsig57 can be used as a receptor for delivering gene therapy or other therapeutic molecules to target cells and tissues.
- zsig57 can be used to deliver a polynucleotide encoding a polypeptide, or alternatively, a chemotherapeutic agent, to tissues in which it is expressed, for example bone marrow or PBLs, or intestine.
- a DNA carrier consisting of an Fab portion of an anti-zsig57 antibody can be constructed to introduce a plasmid that contains a cDNA encoding a functional polypeptide , e.g., a cDNA encoding a polypeptide of therapeutic interest.
- the cDNA encoding a functional polypeptide would generally be selected to provide, upon expression within the cell, a functional polypeptide where a defective or non-functional polypeptide is present.
- a functional polypeptide where a defective or non-functional polypeptide is present.
- Such an anti-zsig57 antibody upon binding to the zsig57 molecule on the cell surface will be endocytosed or otherwise transported into the cell, wherein the functional polypeptide is expressed within the cell. See, e.g., Ferkol, T. et al . , Am. Soc. Clin. Invest. 9£:493-502, 1995; Ferkol, T. et al . , Gene Therapy 3 : 669-678, 1996.
- chemical moieties can be cross-linked to anti-zsig57 antibodies for chemical delivery to cells in the same manner and used, for example, to deliver chemotherapeutic agents to tumor cells. Coupling of chemicals to antibodies is well known in the art and described herein.
- this zsig57 therapy delivery system can be used in vivo or ex vivo as described above (See, e.g., Wu et al . , supra) .
- tissues receptive to delivery of such zsig57- mediated therapy include bone marrow, PBLs, and intestine, and other tissues and cells in which zsig57 is normally expressed, or where zsig57 is introduced by methods known in the art.
- Antisense methodology can be used to inhibit zsig57 gene transcription, such as to inhibit cell proliferation in vivo.
- Polynucleotides that are complementary to a segment of a zsig57-encoding polynucleotide e.g., a polynucleotide as set froth in SEQ ID NO:l
- Such antisense polynucleotides are used to inhibit expression of zsig57 polypeptide-encoding genes in cell culture or in a subject .
- the present invention also provides reagents which will find use in diagnostic applications.
- the zsig57 gene a probe comprising zsig57 DNA or RNA or a subsequence thereof can be used to determine if the zsig57 gene is present on chromosome 6 or if a mutation has occurred.
- Zsig57 is located at the 6p21.1- p21.2 region of chromosome 6 (see, Example 3).
- Detectable chromosomal aberrations at the zsig57 gene locus include, but are not limited to, aneuploidy, gene copy number changes, insertions, deletions, restriction site changes and rearrangements.
- the precise knowledge of a gene's position can be useful for a number of purposes, including: 1) determining if a sequence is part of an existing contig and obtaining additional surrounding genetic sequences in various forms, such as YACs, BACs or cDNA clones; 2) providing a possible candidate gene for an inheritable disease which shows linkage to the same chromosomal region; and 3) cross-referencing model organisms, such as mouse, which can aid in determining what function a particular gene might have.
- the zsig57 gene is located within the major histocompatability (MHC) locus, which encodes proteins involved with antigen presentation to T-cells . Proteins and polypeptides are processed and then complexed with MHC molecules followed by transport to the cell surface for presentation to T-cells. A number of accessory molecules are encoded in the MHC locus that are essential for antigen processing and presentation. For example, TAP transporters and tapasin function to transport and assemble peptides plus MHC respectively (Herberg, J.A., et al., Eur. J. Immunol., £8:459-467, 1998).
- zsig57 polypeptide may be involved in antigen presentation, as a chaparone, transporter, trafficking element, or other processing and presentation function.
- Antigen presentation can be measured in standard assays known in the art: for example, antigen presentation for cytotoxic T-cells, such as the chromium release assay (Hosken, N.A., and Bevan, M.J., J. Exp . Med. £75:719-729, 1992); and proliferation and IL-2 production by T-cells in response to antigen presenting cells (Rudensky, A.Y., et al . , Nature 353:660-662, 1991; Roosnek, E., and Lanzavecchia, J. Exp. Med.
- mice engineered to express the zsig57 gene, referred to as "transgenic mice,” and mice that exhibit a complete absence of zsig57 gene function, referred to as “knockout mice,” may also be generated (Snouwaert et al . , Science 252:1083, 1992; Lowell et al . , Nature 366:740-42, 1993; Capecchi, M.R., Science 2££: 1288-1292, 1989; Palmiter, R.D. et al . Annu Rev Genet. 20: 465-499, 1986).
- transgenic mice that over-express zsig57, either ubiquitously or under a tissue-specific or tissue- restricted promoter can be used to ask whether over- expression causes a phenotype.
- over- expression of a wild-type zsig57 polypeptide, polypeptide fragment or a mutant thereof may alter normal cellular processes, resulting in a phenotype that identifies a tissue in which zsig57 expression is functionally relevant and may indicate a therapeutic target for the zsig57, its agonists or antagonists.
- a preferred transgenic mouse to engineer is one that over-expresses the mature zsig57 polypeptide (approximately amino acids 18 (He) or residue 16 (Gin) to residue 199 (Gin) of SEQ ID NO:2). Moreover, such over-expression may result in a phenotype that shows similarity with human diseases.
- knockout zsig57 mice can be used to determine where zsig57 is absolutely required in vivo. The phenotype of knockout mice is predictive of the in vivo effects of that a zsig57 antagonist, such as those described herein, may have.
- the human zsig57 cDNA can be used to isolate murine zsig57 mRNA, cDNA and genomic DNA, which are subsequently used to generate knockout mice. These mice may be employed to study the zsig57 gene and the protein encoded thereby in an in vivo system, and can be used as in vivo models for corresponding human diseases. Moreover, transgenic mice expression of zsig57 antisense polynucleotides or ribozymes directed against zsig57, described herein, can be used analogously to transgenic mice described above.
- the proteins of the present invention are formulated for parenteral, particularly intravenous or subcutaneous, delivery according to conventional methods.
- Intravenous administration will be by bolus injection or infusion over a typical period of one to several hours.
- pharmaceutical formulations will include a zsig57 protein in combination with a pharmaceutically acceptable vehicle, such as saline, buffered saline, 5% dextrose in water or the like.
- Formulations can further include one or more excipients, preservatives, solubilizers, buffering agents, albumin to prevent protein loss on vial surfaces, etc.
- Therapeutic doses will generally be in the range of 0.1 to 100 ⁇ g/kg of patient weight per day, preferably 0.5-20 mg/kg per day, with the exact dose determined by the clinician according to accepted standards, taking into account the nature and severity of the condition to be treated, patient traits, etc. Determination of dose is within the level of ordinary skill in the art. The invention is further illustrated by the following non-limiting examples.
- Oligonucleotide primers were designed from the sequence of the identified EST. The primers were used for priming internally within the EST to identify tissues from which a full-length clone could be isolated.
- a PCR amplification reaction was performed on Marathon-ready cDNA (Clontech) from a variety of tissues: Brain, Liver, placenta, monocytes, bone marrow and spleen.
- a PCR reaction was run using oligonucleotides ZC 16,174 (SEQ ID NO: 8) and ZC 16,175
- the resulting DNA products were electrophoresed on a 1.5% agarose gel, and an expected band at approximately 200 bp was seen in reactions using the bone marrow, monocyte and spleen cDNA libraries as a template.
- the DNA .band from the bone marrow sample was gel purified using a commercially available kit (QiaexIITM; Qiagen) and sequenced. Sequence analyses of the subclone confirmed that the PCR product included the EST DNA sequence.
- Example 2 Tissue Distribution Northern blot analysis was performed using Human Multiple Tissue Blots (MTN I, MTN II, and MTN III) (Clontech) .
- the 200 bp PCR product from bone marrow, described in Example 1 was purified using a commercially available kit (QiaexIITM; Qiagen) and then radioactively labeled with 32 P-dCTP using Prime-It II, a random prime labeling system (Stratagene Cloning Systems), according to the manufacturer's specifications.
- the probe was then purified using a Nuc-TrapTM column (Stratagene) according to the manufacturer's instructions.
- ExpressHybTM Human Multiple Tissue Blots
- Dot Blots were also performed using Human RNA Master BlotsTM (Clontech) .
- the methods and conditions for the Dot Blots are the same as for the Multiple Tissue Blots disclosed above. Strong signal intensity was present in small intestine, liver and kidney.
- Example 3 PCR-Based Chromosomal Mapping of the zsig57 Gene
- the GeneBridge 4 Radiation Hybrid Panel contains DNAs from each of 93 radiation hybrid clones, plus two control DNAs (the HFL donor and the A23 recipient) .
- a publicly available WWW server http://www-genome.wi.mit.edu/cgi- bin/contig/rhmapper .pi) allows mapping relative to the Whitehead Institute/MIT Center for Genome Research's radiation hybrid map of the human genome (the "WICGR" radiation hybrid map) which was constructed with the GeneBridge 4 Radiation Hybrid Panel .
- WWW server http://www-genome.wi.mit.edu/cgi- bin/contig/rhmapper .pi
- WICGR Whitehead Institute/MIT Center for Genome Research's radiation hybrid map of the human genome
- the reactions were overlaid with an equal amount of mineral oil and sealed.
- the PCR cycler conditions were as follows: an initial 1 cycle 5 minute denaturation at 95°C; 35 cycles of a 1 minute denaturation at 95°C, 1 minute annealing at 60°C, and 1.5 minute extension at 72°C; followed by a final 1 cycle extension of 7 minutes at 72°C.
- the reactions were separated by electrophoresis on a 2% agarose gel (Life Technologies) .
- zsig57 maps 2.12 cR_3000 from the framework marker AFM165YD12 on the chromosome 6 WICGR radiation hybrid map.
- Proximal and distal framework markers were AFM165YD12 and WI-6092, respectively.
- the use of surrounding markers positions zsig57 in the 6p21.1- p21.2 region on the integrated LDB chromosome 6 map (The Genetic Location Database, University of Southhampton, WWW server: http://cedar.genetics.soton.ac.uk/public_html/).
- ZSG57NE and zSG57CE Two expression vectors were prepared to express zsig57 polypeptides in insect cells: ZSG57NE, designed to express a zsig57 polypeptide with a N-terminal Glu-Glu tag
- the cell pellet was thawed and lysed under hypotonic conditions to determine if there was any protein which was: a) produced but staying in the cell (i.e., detergent extractable) or b) insoluble.
- the Hypotonic Lysis Procedure is as follows: (1) Thaw cell pellets; (2) Add 2.5ml hypotonic lysis buffer (HLB) to each pellet and resuspend.
- HLB hypotonic lysis buffer
- a Western blot was performed on the following samples: the zSG57NE(e) culture supernatant, the zSG57NE(e) detergent extractable fraction, the zSG57NE(e) insoluble fraction.
- the antibody, made in house, used for detection was a mouse anti-Glu-Glu, HRP conjugated antibody (3mg/mL), used at a 1:2000 dilution (1.5 ⁇ g/mL). 90% of the zSG57NE protein was in the culture supernatant, with very small amounts in the detergent extractable and insoluble fractions.
- a zsig57 DNA fragment having a C-terminal Glu- Glu tag was generated by PCR, as described above, using ZC17,116 (SEQ ID NO:18) and ZC17,479 (SEQ ID N0:19) as PCR primers and the plasmid containing zsig57, described in Example 1, as a template.
- the 100 ⁇ l PCR reaction was run as described above.
- the PCR product was verified on an agarose gel, digested, and gel isolated, as described above.
- the DNA band was, diluted to 0.5% agarose with 2 mM MgCl 2 , melted at 68°C and ligated into a BamHI/Xbal digested baculovirus expression vector, described above.
- Approximately 49 nanograms of the restriction digested zsig57CE insert and approximately 229 ng of the BamHI/Xbal digested transfer vector were ligated as described above.
- Ura + yeast transformants from a single plate were resuspended in 2.5 ml H 2 O and spun briefly to pellet the yeast cells.
- the cell pellet was resuspended in 1 ml of lysis buffer (2% Triton X-100, 1% SDS, 100 mM NaCl, 10 mM Tris, pH 8.0, 1 mM EDTA) .
- lysis buffer 2% Triton X-100, 1% SDS, 100 mM NaCl, 10 mM Tris, pH 8.0, 1 mM EDTA
- Five hundred microliters of the lysis mixture was added to an Eppendorf tube containing 300 ⁇ l acid washed glass beads and 200 ⁇ l phenol-chloroform, vortexed for 1 minute intervals two or three times, followed by a 5 minute spin in a Eppendorf centrifuge as maximum speed.
- ADE DS 0.056% -Ade -Trp -Thr powder, 0.67% yeast nitrogen base without amino acids, 2% D-glucose, 0.5% 200X tryptophan, threonine solution, and 18.22% D-sorbitol
- the PCR reaction product was loaded onto a 1.2 % (low melt) SeaPlaque GTG (FMC, Rockland, ME) gel in TAE buffer.
- the zsig57 PCR product was excised from the gel and purified using the QIAquickTM PCR Purification Kit gel cleanup kit (Qiagen) as per kit instructions.
- the PCR product was then digested with Fsel-Ascl, phenol/chloroform extracted, EtOH precipitated, and rehydrated in 20ml TE (Tris/EDTA pH 8 ) .
- the 600 bp zsig57 fragment was then ligated into the Fsel-Ascl sites of the transgenic vector pMT12-8 (See, Example 8) and transformed into DH10B competent cells by electroporation. Clones containing zsig57 were identified by plasmid DNA miniprep followed by digestion with Fsel-Ascl . A positive clone was sent to the sequencing department to insure there are no deletions or other anomalies in the construct. The sequence of zsig57 cDNA was confirmed. Qiagen Maxi Prep protocol (Qiagen) is used to generate DNA to continue our process described below. The 600 bp zsig57 cDNA was released from the
- TG12-8 vector using Fsel and Ascl enzymes.
- the cDNA was isolated on a 1% low melt SeaPlaque GTGTM (FMC, Rockland, ME) gel and was then excised from the gel and the gel slice melted at 70°C, extracted twice with an equal volume of Tris buffered phenol, and EtOH precipitated. The DNA was resuspended in lO ⁇ l H 2 0.
- the crude lysate was amplified (Primary (1°) amplification) to obtain a working "stock" of zsig57 rAdV lysate.
- Ten 10cm plates of nearly confluent (80-90%) 293A cells were set up 20 hours previously, 200ml of crude rAdV lysate added to each 10cm plate and monitored for 48 to 72 hours looking for CPE under the white light microscope and expression of GFP under the fluorescent microscope.
- CPE Cytopathic Effect
- NP-40 detergent was added to a final concentration of 0.5% to the bottles of crude lysate in order to lyse all cells.
- Bottles were placed on a rotating platform for 10 min. agitating as fast as possible without the bottles falling over.
- the debris was pelleted by centrifugation at 20,000 X G for 15 minutes.
- the supernatant was transferred to 250 ml polycarbonate centrifuge bottles and 0.5 volumes of 20%PEG8000/2.5M NaCl solution added.
- the bottles were shaken overnight on ice.
- the bottles were centrifuged at 20,000 X G for 15 minutes and supernatant discarded into a bleach solution.
- the white precipitate in two vertical lines along the wall of the bottle on either side of the spin mark is the precipitated virus/PEG.
- the precipitate from 2 bottles was resuspended in 2.5 ml PBS.
- the virus solution was placed in 2 ml microcentrifuge tubes and centrifuged at 14,000 X G in the microfuge for 10 minutes to remove any additional cell debris.
- the supernatant from the 2ml microcentrifuge tubes was transferred into a 15ml polypropylene snapcap tube and adjusted to a density of 1.34g/ml with cesium chloride (CsCl) .
- the volume of the virus solution was estimated and 0.55 g/ml of CsCl added.
- the CsCl was dissolved and 1 ml of this solution weighed 1.34 g.
- 25M (Pharmacia) were used to desalt the virus preparation.
- the column was equilibrated with 20 ml of PBS. The virus was loaded and allowed it to run into the column. 5 ml of
- TCID 50 formulation used was as per Quantum Biotechnologies, Inc., above.
- the titer (T) is determined from a plate where virus used is diluted from 10 to 10 , and read 5 days after the infection. At each dilution a ratio (R) of positive wells for CPE per the total number of wells is determined.
- the zsig57 adenovirus had a titer of 5.6 X 10 pfu/ml .
- the mixture was then poured into a 5.0 x 20.0 cm Econo-Column (Bio-Rad, Laboratories, Hercules, CA) and the gel was washed with 30 column volumes of phosphate buffered saline (PBS) . The unretained flow-through fraction was discarded. Once the absorbence of the effluent at 280 nM was less than 0.05, the flow through the column was reduced to zero and the anti-EE Sepharose gel was eluted batchwise with 2.0 column volumes of PBS containing 0.4 mg/ml of EE peptide (AnaSpec, San Jose, CA) .
- PBS phosphate buffered saline
- the EE peptide used for bothe CEE and NEE zsig57 constructs has the sequence GluTyrMetProValAsp (SEQ ID NO: 28) .
- SEQ ID NO: 28 The EE peptide used for bothe CEE and NEE zsig57 constructs was the sequence GluTyrMetProValAsp (SEQ ID NO: 28) .
- the anti-EE Sepharose gel was then washed with 2.0 column volumes of 0.1M glycine, pH 2.5, and the glycine wash was collected separately.
- the pH of the glycine-eluted fraction was adjusted to 7.0 by the addition of a small volume of 10X PBS and stored at 4°C for future analysis if needed.
- the peptide elution fraction was concentrated to 5.0 ml using a 3,000 molecular weight cutoff membrane concentrator (Millipore, Bedford, MA) according to the manufacturer's instructions.
- the pure zsig57 NEE or CEE protein in the peptide elution fraction was separated from contaminating free peptide by chromatography of the peptide elution fraction on a 1.5 x 50 cm Sephadex G-50
- the zsig57 NEE preparation contained one major band of apparent molecular weight 14,000. The mobility of this band was the same in the presence and absence of reducing agents and was visible on western blots with anti-EE antibodies.
- the zsig57 CEE purified protein also showed one major band at 14,000 Da on Coomassie-Blue stained SDS- PAGE gels.
- Western blotting with anti-EE antibodies showed one major band of cross-reactive material at 14,000 Da. The mobility of the 14,000 Da band on western blots was not changed by the presence or absence of reducing agents .
- the pure material was concentrated as described above, analyzed by SDS-PAGE and Western blotting with anti-EE antibodies, and samples were taken for amino acid analysis and N-terminal sequencing. The remainder of the sample was aliquoted, and stored at - 80°C according to our standard procedures. The concentration of the purified zsig57 NEE was 0.3 mg/ml.
- Electrophoresis on SDS-PAGE gels in the absence of reducing agents showed two Coomassie Blue stained bands of apparent molecular weights 14,000 and 28,000. Each of these bands showed cross-reactivity on western blots with anti-EE IgG. In the presence of reducing agents, in contrast, only one Coomassie Blue-stained band of 14,000 Da was observed and this band was the only protein that showed cross-reactivity with anti-EE antibodies on Western blots.
- a 100 ml bed volume of protein G-Sepharose (Pharmacia, Piscataway, NJ) was washed 3 times with 100 ml of PBS containing 0.02% sodium azide using a 500 ml Nalgene 0.45 micron filter unit.
- the gel was washed with 6.0 volumes of 200 mM triethanolamine, pH 8.2 (TEA, Sigma, St. Louis, MO) . and an equal volume of EE antibody solution containing 900 mg of antibody was added. After an overnight incubation at 4°C, unbound antibody was removed by washing the resin with 5 volumes of 200 mM TEA as described above.
- the resin was resuspended in 2 volumes of TEA, transferred to a suitable container, and dimethylpimilimidate-2HCl (Pierce, Rockford, IL) , dissolved in TEA, was added to a final concentration of 36 mg/ml of gel.
- the gel was rocked at room temperature for 45 min and the liquid was removed using the filter unit as described above. Nonspecific sites on the gel were then blocked by incubating for 10 min at room temperature with 5 volumes of 20 mM ethanolamine in 200 mM TEA. The gel was then washed with 5 volumes of PBS containing 0.02% sodium azide and stored in this solution at 4°C.
- Oligonucleotides were designed to generate a PCR fragment containing a consensus Kozak sequence and the exact zsig57 coding region. These oligonucleotides were designed with an Fsel site at the 5' end and an Ascl site at the 3' end to facilitate cloning into pMT12-8, our standard transgenic vector.
- PMT12-8 contains the mouse MT-1 promoter and a 5' rat insulin II intron upstream of the Fsel site.
- PCR reactions were carried out with 200 ng zsig57 plasmid template (Example 1) and oligonucleotides ZC17,529 (SEQ ID NO:26) and ZC17,530 (SEQ ID NO:27) as primers.
- PCR reaction conditions were as follows: 95°C for 5 minutes, wherein Advantage® cDNA polymerase (Clontech) was added; 15 cycles of 95°C for 60 seconds, 62°C for 60 seconds, and 72°C for 90 seconds; and 72°C for 7 minutes.
- PCR products were separated by agarose gel electrophoresis and purified using a QiaQuickTM (Qiagen) gel extraction kit.
- the isolated, 599 bp, DNA fragment was digested with Fsel and Ascl (Boerhinger-Mannheim) , ethanol precipitated and ligated into pMT12-8 that was previously digested with Fsel and Ascl.
- the pMT12-8 plasmid designed for expression of a gene of interest in transgenic mice, contains an expression cassette flanked by 10 kb of MT-1 5' DNA and 7 kb of MT-1 3' DNA.
- the expression cassette comprises the MT-1 promoter, the rat insulin II intron, a polylinker for the insertion of the desired clone, and the human growth hormone poly A sequence.
- a Sail fragment containing with 5' and 3' flanking sequences, the MT-1 promoter, the rat insulin II intron, zsig57 cDNA and the human growth hormone poly A sequence was prepared to be used for microinjection into fertilized murine oocytes.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU41974/99A AU4197499A (en) | 1998-06-18 | 1999-05-20 | Immunomodulator polypeptide, zsig57 |
CA002331253A CA2331253A1 (en) | 1998-06-18 | 1999-05-20 | Immunomodulator polypeptide, zsig57 |
JP2000554849A JP2002518009A (en) | 1998-06-18 | 1999-05-20 | Immunomodulator-polypeptide ZSIG57 |
IL14012099A IL140120A0 (en) | 1998-06-18 | 1999-05-20 | Immunomodulator polypeptide zsig57 |
EP99925747A EP1088068A1 (en) | 1998-06-18 | 1999-05-20 | Immunomodulator polypeptide, zsig57 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9960098A | 1998-06-18 | 1998-06-18 | |
US09/099,600 | 1998-06-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999066040A1 true WO1999066040A1 (en) | 1999-12-23 |
Family
ID=22275781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/011337 WO1999066040A1 (en) | 1998-06-18 | 1999-05-20 | Immunomodulator polypeptide, zsig57 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1088068A1 (en) |
JP (1) | JP2002518009A (en) |
AU (1) | AU4197499A (en) |
CA (1) | CA2331253A1 (en) |
IL (1) | IL140120A0 (en) |
WO (1) | WO1999066040A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001066693A1 (en) * | 2000-03-10 | 2001-09-13 | Novozymes A/S | Compositions and methods for producing high yields of heterologous polypeptides in a pichia cell |
-
1999
- 1999-05-20 AU AU41974/99A patent/AU4197499A/en not_active Abandoned
- 1999-05-20 EP EP99925747A patent/EP1088068A1/en not_active Withdrawn
- 1999-05-20 WO PCT/US1999/011337 patent/WO1999066040A1/en not_active Application Discontinuation
- 1999-05-20 IL IL14012099A patent/IL140120A0/en unknown
- 1999-05-20 CA CA002331253A patent/CA2331253A1/en not_active Abandoned
- 1999-05-20 JP JP2000554849A patent/JP2002518009A/en not_active Withdrawn
Non-Patent Citations (4)
Title |
---|
DAISH A. ET AL.: "Expression of the CMRF-35 antigen, a new member of the imunoglobulin gene superfamily, is differentially regulated on leukocytes", IMMUNOLOGY, vol. 79, 1993, pages 55 - 63, XP002116338 * |
DATABASE GENBANK 19 December 1997 (1997-12-19), HILLIER L. ET AL.: "EST; H. sapiens fetal liver cDNA clone 433289", XP002116339 * |
KUSHIRO A ET AL: "Polymeric immunoglobulin receptor gene of mouse: sequence, structure and chromosomal location", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, vol. 204, no. 1-2, 19 December 1997 (1997-12-19), pages 277-282, XP004100723, ISSN: 0378-1119 * |
VERBEET M P ET AL: "Cloning and characterization of the bovine polymeric immunoglobulin receptor-encoding cDNA", GENE, vol. 164, no. 2, 27 October 1995 (1995-10-27), pages 329-333, XP004041896, ISSN: 0378-1119 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001066693A1 (en) * | 2000-03-10 | 2001-09-13 | Novozymes A/S | Compositions and methods for producing high yields of heterologous polypeptides in a pichia cell |
Also Published As
Publication number | Publication date |
---|---|
JP2002518009A (en) | 2002-06-25 |
EP1088068A1 (en) | 2001-04-04 |
IL140120A0 (en) | 2002-02-10 |
AU4197499A (en) | 2000-01-05 |
CA2331253A1 (en) | 1999-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1009829B1 (en) | Adipocyte-specific protein homologs | |
WO1999007740A2 (en) | Lipocalin homologs | |
EP1002075B1 (en) | Adipocyte-specific protein homologs | |
US20050240014A1 (en) | Connective tissue growth factor homologs | |
EP0968288B1 (en) | A HUMAN 2-19 PROTEIN HOMOLOGUE, z219a | |
CA2289118A1 (en) | Novel tumor antigens | |
EP1032665A1 (en) | A human 2-19 protein homologue, z219c | |
US6902911B1 (en) | Human 2-19 protein homologue z219C | |
EP1088068A1 (en) | Immunomodulator polypeptide, zsig57 | |
MXPA00012591A (en) | Immunomodulator polypeptide, zsig57 | |
AU2870399A (en) | Connective tissue growth factor homologs | |
US20020182677A1 (en) | Pancreatic and ovarian polypeptide, zsig58 | |
WO1999028467A1 (en) | Human thyroid protein zsig45 and dna encoding same | |
AU1607800A (en) | Ring finger protein zapop3 | |
MXPA00008094A (en) | Connective tissue growth factor homologs | |
ZA200100671B (en) | Pancreatic and ovarian polyptetide ZSIG58. | |
EP1102846A1 (en) | Pancreatic and ovarian polypeptide, zsig58 | |
MXPA01012181A (en) | Secreted alpha-helical protein-31. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 140120 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999925747 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/012591 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2000 554849 Country of ref document: JP Kind code of ref document: A Ref document number: 2331253 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 41974/99 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1999925747 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999925747 Country of ref document: EP |